These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 12580647)

  • 1. Safety of celecoxib in individuals allergic to sulfonamide: a pilot study.
    Shapiro LE; Knowles SR; Weber E; Neuman MG; Shear NH
    Drug Saf; 2003; 26(3):187-95. PubMed ID: 12580647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy.
    Knowles S; Shapiro L; Shear NH
    Drug Saf; 2001; 24(4):239-47. PubMed ID: 11330653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonamide Hypersensitivity: Fact and Fiction.
    Khan DA; Knowles SR; Shear NH
    J Allergy Clin Immunol Pract; 2019; 7(7):2116-2123. PubMed ID: 31495421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing.
    Tornero P; De Barrio M; Baeza ML; Herrero T
    Contact Dermatitis; 2004 Aug; 51(2):57-62. PubMed ID: 15373844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
    Liccardi G; Salzillo A; Piccolo A; Senna G; Piscitelli E; D'Amato M; D'Amato G
    Eur Ann Allergy Clin Immunol; 2005 Feb; 37(2):50-3. PubMed ID: 15859361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic tolerability profile of celecoxib.
    Patterson R; Bello AE; Lefkowith J
    Clin Ther; 1999 Dec; 21(12):2065-79. PubMed ID: 10645754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs].
    Ahlbach S; Usadel KH; Kaufmann R; Boehncke WH
    Med Klin (Munich); 2003 Apr; 98(5):242-4. PubMed ID: 12721666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib-induced erythema multiforme with glyburide cross-reactivity.
    Ernst EJ; Egge JA
    Pharmacotherapy; 2002 May; 22(5):637-40. PubMed ID: 12013363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfonamide allergies and outcomes related to use of potentially cross-reactive drugs in hospitalized patients.
    Hemstreet BA; Page RL
    Pharmacotherapy; 2006 Apr; 26(4):551-7. PubMed ID: 16553515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database.
    Wiholm BE
    Curr Med Res Opin; 2001; 17(3):210-6. PubMed ID: 11900314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE.
    Lander SA; Wallace DJ; Weisman MH
    Lupus; 2002; 11(6):340-7. PubMed ID: 12139371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute generalized exanthematous pustulosis caused by celecoxib.
    Yang CC; Lee JY; Chen WC
    J Formos Med Assoc; 2004 Jul; 103(7):555-7. PubMed ID: 15318279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolic rationale for a lack of cross-reactivity between sulfonamide antimicrobials and other sulfonamide-containing drugs.
    Lehmann DF
    Drug Metab Lett; 2012 Jun; 6(2):129-33. PubMed ID: 23157194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allergic skin reaction to celecoxib.
    Grob M; Scheidegger P; Wüthrich B
    Dermatology; 2000; 201(4):383. PubMed ID: 11146365
    [No Abstract]   [Full Text] [Related]  

  • 16. Sulfonamide allergy without cross-reactivity to celecoxib.
    Figueroa J; Ortega N; Almeida L; Blanco C; Castillo R
    Allergy; 2007 Jan; 62(1):93. PubMed ID: 17156357
    [No Abstract]   [Full Text] [Related]  

  • 17. Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation.
    Kleinhans M; Linzbach L; Zedlitz S; Kaufmann R; Boehncke WH
    Contact Dermatitis; 2002 Aug; 47(2):100-2. PubMed ID: 12423408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
    Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction.
    Pyle RC; Butterfield JH; Volcheck GW; Podjasek JC; Rank MA; Li JT; Harish A; Poe KL; Park MA
    J Allergy Clin Immunol Pract; 2014; 2(1):52-8. PubMed ID: 24565769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
    Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
    Ann Allergy Asthma Immunol; 2005 Aug; 95(2):154-8. PubMed ID: 16136765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.